

5 **NOVEL BIOCONJUGATES AS THERAPEUTIC AGENT AND
SYNTHESIS THEREOF**

FIELD OF INVENTION

The present disclosure provides bioconjugates for target delivery of a compound wherein the bioconjugates are useful as therapeutic and/ or diagnostic agent. The
10 disclosure further provides a process for preparation of the bioconjugates.


BACKGROUND OF THE INVENTION

Development of new methods for linking sugars to peptides or proteins is an active area of research (Brik A, Ficht S, Yang YY, Bennett CS and Wong C-H (2006) J Am Chem Soc 128: 15026-33; Brik A, Ficht S and Wong C-H (2006)
15 Curr Opin Struct Biol 10: 638-44; Wu B, Chen J, Warren JD, Chen G, Hua Z and Danishefsky SJ (2006) Angew Chem 45: 4116-45; Buskas J, Ingale S and Boons GJ (2006) Glycobiology 16: 113R-136R.), because natural or neoglycoconjugates play important roles in biology and medicine and are indispensable tools for probing several biological processes (Doores KJ, Gamblin DP and Davis BG
20 (2006) Chem Eur J 12: 656-665).

However, despite dramatic progress in synthetic carbohydrate and protein chemistry in recent years, glycoconjugate synthesis involving sugar and a polypeptide remains a formidable task. This is principally because synthetic protocols are quite demanding and involve multiple reaction steps with
25 requirements of rather extensive protection of reactive functionalities. The problem may be in part or completely obviated through the intermediary of enzymes. Indeed, glycosidases and glycosyl transferases, in appropriate situations, have made the oligosaccharide synthesis much simpler (Koeller KM and Wong C-H (2000) Chem Rev 100: 4465; Sears P and Wong C-H (2001)
30 Science 291: 2344-2350.)

5 Given the current ease with which peptides are assembled by solid phase methodology and proteins obtained from expression systems, the availability of an enzyme capable of covalently linking a pre-synthesized sugar and a polypeptide would greatly facilitate the 'convergent' semisynthesis of glycopeptide or protein mimetics (neoglycoconjugates) with exquisite biological properties.

The bacterial transpeptidase sortase, present in the cell envelope of most gram-positive organisms, catalyzes the covalent anchoring of several virulence-related bacterial surface proteins to the peptidoglycan cross-bridges of the cell wall (Marraffini LA, Dedent AC and Schneewind O (2006) Microbiol Mol Biol Rev 70: 192-221). Sortase A of *Staphylococcus aureus* recognizes a LPXTG like sequence motif located near the C-terminus of the target proteins, cleaves at Thr-Gly peptide bond, and catalyzes the formation of a new peptide bond between threonyl carboxyl and amino group of the peptidoglycan penta-glycine cross-bridges (Marraffini LA, Dedent AC and Schneewind O (2006) Microbiol Mol Biol Rev 70: 192-221; Ton-That H, Liu G, Mazmanian SK, Faull KF and Schneewind O (1999) Proc Natl Acad Sci USA 96: 12424-29). This is illustrated below:



The transpeptidation reaction proceeds in two steps without the aid of ATP or any other extraneous molecule; active site cysteine residue first attacks the target LPXTG substrate forming an acyl-enzyme intermediate which in the second step is resolved by the nucleophilic attack of the amino group of terminal Gly residue of the peptidoglycan. In the absence of a suitable amino nucleophile, LPXTG peptide substrate is slowly hydrolyzed (Marraffini LA, Dedent AC and Schneewind O (2006) Microbiol Mol Biol Rev 70: 192-221; Ton-That H, Liu G, Mazmanian SK, Faull KF and Schneewind O (1999) Proc Natl Acad Sci USA 96: 12424-29). The ligation of LPXTG containing short or long polypeptide sequences to polypeptide fragments containing even a single Gly residue at the

5 amino terminal has been shown to proceed *in vitro* (Mao H, Hart SA, Schink A
and Pollok BA (2004) J Am Chem Soc 126: 2670-71). Mao et al (2004) have
recently demonstrated the utility of sortase-mediated protein ligation as a tool for
protein engineering by applying this approach to the synthesis of protein-peptide
conjugates that would have been rather difficult to obtain by chemical or genetic
10 methods.

SUMMARY OF THE INVENTION

The present disclosure provides bioconjugates for target delivery of a compound
wherein the bioconjugates are useful as therapeutic and/ or diagnostic agent. The
disclosure further provides a process for preparation of the bioconjugates.

15 In one aspect, the present disclosure provides therapeutic and/or diagnostic
bioconjugates useful for target delivery of a compound, wherein the bioconjugate
comprises:

- a. a substrate comprising LPXTG peptide motif capable of recognizing
sortase, wherein said substrate is selected from a group consisting of
20 peptides, polypeptides, proteins, glycoprotein, lipoprotein, antibodies,
radionucleotides, fluorphores, ligand chromophore and any compound
comprising the LPXTG peptide motif; and
- b. a biomolecule selected from a group consisting of aminoglycoside,
polyamines, aminosugars, hydroxyamino acids, hydroxyamino acid
25 esters, aminolipids and any other compound comprising these moieties.

In another aspect, the present disclosure provides a process for preparation of the
bioconjugate, wherein the process comprises:

- a. providing a substrate comprising LPXTG peptide motif capable of
recognizing sortase, wherein said substrate is selected from a group
30 consisting of peptides, polypeptides, proteins, glycoprotein, lipoprotein,

- 5 antibodies, radionucleotides, fluorphores, ligand chromophore and any compound comprising the LPXTG peptide motif;
- b. providing a biomolecule selected from a group consisting of aminoglycoside, aminosugars, polyamines, hydroxyamino acids, hydroxyamino acid esters aminolipids and any compound comprising these
- 10 moieties;
- c. providing sortase to catalyze the ligation reaction of said substrate and said biomolecule under suitable conditions to obtain said bioconjugate

In yet another aspect, the present disclosure provides a composition useful as therapeutic or diagnostic agent comprising the bioconjugate disclosed in the

15 present invention and pharmaceutically acceptable salts thereof.

In still another aspect, the present disclosure provides a kit useful for therapy and/or diagnosis wherein the kit comprises the bioconjugate of the present invention and reagents suitable for administering said bioconjugate to an individual.

20 **BRIEF DESCRIPTION OF ACCOMPANYING DRAWINGS**

Figure 1 shows analyses (RPHLC and mass) of the Sortase-catalyzed conjugation reaction of YALPETGK to aminosugars

Figure 2 shows RPHPLC analyses of sortase-catalyzed conjugation of YALPETGK to antibiotics

25 Figure 3 shows ESI mass spectrometric characterization of kanamycin A conjugate

Figure 4 shows ESI mass spectrometric characterization of tobramycin conjugate

Figure 5 shows ESI mass spectrometric characterization of ribostamycin conjugate

30

5 Figure 6 shows ESI mass spectrometric characterization of paramomycin conjugate and neomycin B conjugate

Figure 7 shows RPHPLC analyses of Sortase-catalyzed ligation reaction of LPXTG peptides to amikacin and butirosin A

10 Figure 8 shows analyses (RPHPLC and mass) of Sortase-catalyzed ligation reaction of YALPETGK peptide to 4-amino-3-hydroxybutyric acid

Figure 9 shows RPHPLC analyses of sortase catalysed conjugation of Rev-LPXTG peptide to tobramycin and neomycin B

Figure 10 shows analyses (RPHPLC and mass) of Sortase-catalyzed ligation of YALPETGK with spermine.

15 DETAILED DESCRIPTION OF THE INVENTION

Definitions:

The term "Biomolecule" used herein means a biologically relevant molecule that is used to contact molecular entities in a test sample. These biomolecule include at least in part, molecules such as aminosugars, hydroxyamino acids, hydroxyamino acid esters, aminolipids, polyamines, proteins, peptides, enzymes, and antibodies or derivatives thereof; or any molecule having such moieties; or any compound having such moieties. Biomolecules also include unnatural or synthetic molecules structurally derived from the naturally occurring molecules such as aminosugars, hydroxyamino acids, hydroxyamino acid esters, aminolipids, polyamines, proteins, peptides, enzymes, and antibodies or derivatives thereof; or any molecule having such moieties; or any compound having such moieties.

The term "polypeptide" is also intended to denote a peptide or a protein, these three terms being used interchangeably in the present disclosure.

30 The present disclosure provides bioconjugates useful for therapy and/or diagnosis. The present disclosure further provides a method for the preparation of the bioconjugates by a novel sortase catalyzed mechanism.

5 Bioconjugation is a descriptive term for the joining of two or more different
molecular species by chemical or biological means, in which at least one of the
molecular species is a biological macromolecule. This includes, but is not limited
to conjugation of proteins, peptides, polypeptides, polysaccharides, hormones,
nucleic acids, and liposomes with each other or with any other molecular species
10 that add useful properties, including, but not limited to, drugs, radionuclides,
toxins, haptens, inhibitors, chromophores, fluorophores, ligands etc.
Immobilization of biological macromolecules is also considered a special case of
bioconjugation in which the macromolecule is conjugated, either reversibly or
irreversibly, to an insoluble solid phase support. Bioconjugation is utilized
15 extensively in biochemical, immunochemical and molecular biological research.
Major applications of bioconjugation include; detection of gene probes, enzyme-
linked immuno solid-phase assay, and monoclonal antibody drug targeting and
medical imaging.

Bioconjugates are generally classified as either direct or indirect conjugates.
20 Direct conjugates encompass those in which two or more components are joined
by direct covalent chemical linkages. Alternatively, indirect conjugates
encompass those in which two or more components are joined via an
intermediary complex involving a biological molecule.

Surprisingly, the inventors have shown a novel enzymatic approach according to
25 the invention using an unprecedented sortase-catalyzed transpeptidation reaction
between substrate comprising the LPXTG peptide motif and biomolecules such as
aminosugars, hydroxyamino acids, hydroxyamino acid esters, aminolipids,
polyamines; nucleic acids or derivatives thereof; or any molecule having such
moieties; or any compound having such moieties to obtain a bioconjugates useful
30 for target delivery of a compound.

The present disclosure relates to a novel sortase-catalyzed transpeptidation
reaction that leads to amide bond formation between the Threonyl carboxyl of an
LPXTG motif of a substrate and aminosugar such as (hexoaminosugar) hexoses

5 for example 6-amino-6-deoxyhexose for example 6-amino-6-deoxyglucose, 6-amino-6-deoxymannose, 6-amino-6-deoxyallose, 6-amino-6-deoxyaltrose, 6-amino-6-deoxyidose, 6-amino-6-deoxygalactose and 6-amino-6-deoxytalose.

The present disclosure further relates to a novel sortase-catalyzed transpeptidation reaction that leads to amide bond formation between the
10 Threonyl carboxyl of an LPXTG motif of a substrate and hydroxyamino acids (or derivatives thereof) such as 4-amino-3-hydroxybutyric acid and 4-amino-2-hydroxybutyric acid.

The present disclosure further relates to a novel sortase-catalyzed transpeptidation reaction that leads to amide bond formation between the
15 Threonyl carboxyl of an LPXTG motif of a substrate and hydroxyamino acid esterified with alkyl, aromatic and other specific molecular entities such as a cofactor (coenzyme A), viz., 4-amino-3-hydroxybutyryl-coenzyme A, 4-amino-2-hydroxy-butyl-coenzyme A.

The present disclosure further relates to a novel sortase-catalyzed
20 transpeptidation reaction that leads to amide bond formation between the Threonyl carboxyl of an LPXTG motif of a substrate and aminolipids such as lipoamino acid containing lipids viz., N-[(3-hexadecanoyloxy)hexadecanoyl] ornithine and ethanolamine lipids such as virodhamine.


The present disclosure further relates to a novel sortase-catalyzed
25 transpeptidation reaction that leads to amide bond formation between the Threonyl carboxyl of an LPXTG motif of a substrate and polyamines such as spermine, spermidine and agmatine.

The present disclosure provides a method of preparation of bioconjugates using a sortase catalyzed transpeptidation reaction between peptides comprising the
30 LPXTG peptide motif and biomolecules such as aminosugars, hydroxyamino acids, hydroxyamino acid esters, aminolipids, polyamines; or derivatives thereof; or any molecule having such moieties; or any compound having such moieties to


5 obtain a bioconjugates useful for target delivery of a compound. The utility of
this reaction is further demonstrated in the preparation of bioconjugates
consisting of peptides and aminoglycoside antibiotics. Also, since sortases are
known as important therapeutic targets for combating infectivity of gram-positive
bacteria the above substrate-mimetic amino sugar scaffold is useful for designing
10 an aminosugar based inhibitor of the enzyme.

The potential of sortase to ligate LPXTG containing substrates to different
aminosugar moieties to form glycopeptides was tested by the inventors. A
bioconjugates was obtained by sortase catalyzed ligation of LPXTG containing
substrates to 6-amino-6-deoxyglucose.


15 YALPMTGK (SEQ ID NO: 2) was used as a potential sortase substrate. A 1:1
mixture of the peptide and the 6-amino-6-deoxyglucose sugar was incubated with
and without sortase for 4 to 6 hours subsequent to which the reaction mixture was
analyzed by reverse-phase high performance liquid chromatography (RPHPLC)
and other methods known in the art. The RPHPLC chromatographic profile of the
20 sample that contained sortase revealed two new peaks as compared with the
control sample (without sortase). The electrospray mass spectrometric (ESMS)
analyses of the new peaks were in accordance with the calculated mass of
YALPMT or an YALPMT-sugar adduct suggesting that the above amino sugar
could indeed act as a nucleophile in the transamidation reaction catalyzed by
25 sortase. The reaction scheme is as shown below.



- 5 However, the formation of the amide bond between the Threonyl carboxyl of an LPXTG motif and the amino sugar, 2-amino-2-deoxyglucose (glucosamine), by the same mechanism was not observed (as shown in the reaction scheme below).



- 15 It was then explored if 6-amino-6-deoxyhexopyranose could be recognized by sortase when this moiety is present in the context of a larger molecule. For this the ligation of two peptides namely, YALPMTGK (SEQ ID NO: 2) and RRRRRRRRLPMTGK (SEQ ID NO: 4), with aminoglycoside antibiotics such as



5 kanamycin, tobramycin, paramomycin, ribostamycin and neomycin was tested. A
representative reaction scheme is shown above (one OH group was missing in the
structure, that now appears in Times NEW ROMAN). The coupling of each of
the peptides with the individual antibiotics was carried out for 4 to 6 hours at
37°C in the presence of sortase. The RPHPLC of the reaction mixture followed
10 by ESMS analyses of the product indeed confirmed the formation of the expected
peptide-antibiotic conjugate in each case. Details of the ESI mass analyses of
synthetic peptides used in sortase-mediated ligation reactions are provided in
Table 1.

The processes used for the same are described in the examples. The electro-spray
15 mass results and the theoretically expected results for the products are also
tabulated. The values clearly indicate that the products obtained were the
expected bioconjugates. Thus, it was demonstrated that sortase-catalyzed
transamidation reaction can be utilized for constructing therapeutic bioconjugates
consisting of relevant peptides and molecules containing a 6-amino-6-
20 deoxyhexopyranose moiety.

The conjugation of YALPETGK peptide substrate to several antibiotics was also
tested. RPHPLC analyses of the each reaction mixture containing respective
antibiotics and YALPETGK (SEQ ID NO: 1) peptide substrate in the presence of
sortase yielded a new product peak (indicated by an arrow in Figure 2A) besides
25 the hydrolyzed peptide substrate. The yields of the conjugates varied from 35 %
for kanamycin A and B, and about 70% for tobramycin. ESMS was carried out to
delineate the site of peptide attachment in the antibiotics substrate. The presence
of m/z 836.4 in kanamycin A (Figure 3) The three rings of the antibiotics
structure are labeled as A, B and C, and the peptide portion is designated as P.
30 The ions carry the labels based on the part of the structure from which they are
derived. For example, m/z 836.39 labeled as A-P represents a structure in which
ring A is attached to the peptide; m/z 835.4 in kanamycin B and m/z 819.4 in
tobramycin (Figure 4) unequivocally showed occurrence of peptide ligation
exclusively in the ring A at the 6-amino site in these antibiotics.

5 A single peptide-antibiotics conjugate peak was obtained in RPHPLC analyses
when YALPETGK (SEQ ID NO: 1) was used as a peptide substrate in the
presence of sortase and the respective antibiotics (Figure 2 B). The yield of the
product for these antibiotics was in the range of 20-30 %. ESMS analyses showed
that the 6-amino group of ring A was also the site of ligation (m/z 835.4) in the
10 case ribostamycin (Figure 5). However, ESMS fragmentation pattern of
paromomycin and neomycin conjugates (m/z 967.4) showed that sortase-
mediated peptide ligation occurred at the 6-amino site in the D-ring of these
antibiotics (Figures 6A and 6B). This was corroborated by the MS/MS spectra of
doubly charged species (shown in Figures 6C and 6D) of the respective
15 conjugate. The results show that the 6-amino site in the ring A of neomycin B
was refractory to sortase-catalyzed peptide ligation.

Cells take up Polyarginine sequences very efficiently. Therefore, polyarginine
containing aminoglycoside antibiotics such as but not limited to (R)₉LPMT-
Tobramycin, (R)₉LPMT-Neomycin, (R)₉LPMT-Ribostamycin etc, are likely to
20 be taken up by cells more efficiently and be more bio-effective. These [(R)₉LPMT-
Tobramycin, (R)₉LPMT-Neomycin, (R)₉LPMT-Ribostamycin etc] or similar
conjugates may also elicit anti-HIV activity by interfering with the Tat-TAR and
Rev-RRE interactions.

Tat and Rev are two essential regulatory proteins that play important roles in HIV
25 replication. Both Tat and Rev act through structured viral RNA target sites, TAR
in the case of Tat and RRE in the case of Rev. Short arginine rich peptide
sequences derived from Tat and Rev have been shown to mimic the action of
respective parent proteins. Besides, a nonaarginine peptide (R₉) is known to bind
to TAR with the same affinity and specificity as the wild type Tat peptide. Since
30 aminoglycoside antibiotics also bind to TAR and RRE RNA, the bio-conjugates
of the type mentioned above are likely to be potent inhibitors of HIV replication.

Table 2 provides some examples of the various synthetic bioconjugates that are
produced using sortase.

5 One embodiment of the present disclosure provides a novel therapeutic and/or diagnostic bioconjugate useful for target delivery of a compound, wherein the bioconjugate comprises a substrate comprising LPXTG peptide motif capable of recognizing sortase, wherein said substrate is selected from a group consisting of peptides, polypeptides, proteins, glycoprotein, lipoprotein, antibodies,
10 radionucleotides, fluorophores, ligand chromophore and any compound comprising the LPXTG peptide motif; and a biomolecule selected from a group consisting of aminoglycoside, polyamines, aminosugars, hydroxyamino acids, hydroxyamino acid esters, aminolipids and any other compound comprising these moieties.

15 Another embodiment of the present disclosure provides a novel therapeutic and/or diagnostic bioconjugate useful for target delivery of a compound, wherein the substrate is covalently linked to the biomolecule by a sortase catalyzed ligation mechanism.

In one embodiment of the present invention a peptide is used as the substrate for
20 the preparation of the bioconjugates wherein the amino acid sequence of the peptide is as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO: 3 or SEQ ID NO: 4 or SEQ ID NO: 5 or a variant thereof.

Still another embodiment of the present disclosure relates to various aminoglycosides such as ribostamycin, butirosin, paromomycin, neomycin,
25 lividomycin, kanamycin, tobramycin, dibekacin, gentamicin, sisomicin, netilmicin, isepamicin, arbekacin, amikacin, streptomycin, apramycin, hygromycin, neamine, vancomycin and kasugamycin used in the preparation of the bioconjugate disclosed in the present invention.

Still yet another embodiment of the present disclosure provides a novel
30 therapeutic and diagnostic bioconjugate useful for target delivery of a compound, wherein the aminosugar is selected from a group consisting of 6-amino-6-deoxyglucose, 6-amino-6-deoxymannose, 6-amino-6-deoxyallose, 6-amino-6-

5 deoxyaltrose, 6-amino-6-deoxyidose, 6-amino-6-deoxygalactose and 6-amino-6-deoxytalose.

Further embodiment of the present disclosure provides a novel therapeutic and diagnostic bioconjugate useful for target delivery of a compound, wherein the polyamine is selected from a group consisting of spermine, spermidine and
10 agmatine

Yet another embodiment of the present disclosure provides a novel therapeutic and diagnostic bioconjugate useful for target delivery of a compound, wherein the hydroxy amino acid is selected from a group consisting of 4-amino-3-hydroxybutyric acid, 4-amino-2-hydroxybutyric acid and etahnlamine.

15 Still another embodiment of the present disclosure provides a novel therapeutic and diagnostic bioconjugate useful for target delivery of a compound, wherein the hydroxy amino acid ester is selected from a group consisting of 4-amino-3-hydroxybutyryl stearate, 4-amino-3-hydroxybutyryl palmitate, 4-amino-3-hydroxybutyryl acetate, 4-amino-3-hydroxybutyryl propionate, butyrate/ or 4-
20 amino-2-hydroxybutyryl-acetate, 4-amino-2-hydroxybutyryl-propionate, 4-amino-2-hydroxybutyryl-butyrate, 4-amino-2-hydroxybutyryl-stearate, 4-amino-2-hydroxybutyrylpalmitate, 4-amino-2-hydroxy-butyryl-coenzyme A, 4-amino-3-hydroxybutyrylpalmitate, 4-amino-2-hydroxybutyryl-coenzyme A.

Still yet another embodiment of the present disclosure provide a novel therapeutic
25 and diagnostic bioconjugate useful for target delivery of a compound, wherein the amino lipid is N-[(3-hexadecanoyloxy)hexadecanoyl] ornithine or virodhamine.

Further embodiment of the present disclosure provides a process of preparing the bioconjugate, said process comprising:

30 a. providing a substrate comprising LPXTG peptide motif capable of recognizing sortase, wherein said substrate is selected from a group

5 consisting of peptides, polypeptides, proteins, glycoprotein, lipoprotein, antibodies, radionucleotides, fluorphores, ligand, chromophore and any compound comprising the LPXTG peptide motif;

 b. providing a biomolecule selected from a group consisting of
10 aminoglycoside, hexopyranose, polyamines, aminosugars, hydroxyamino acids, hydroxyamino acid esters, aminolipids and any compound comprising these moieties;

 c. providing sortase to catalyze the ligation reaction of said substrate and said biomolecule under suitable conditions to obtain said bioconjugate

Another embodiment of the present disclosure provides a process of preparing the
15 bioconjugate, wherein the sortase is isolated from *Staphylococcus aureus*.

Yet another embodiment of the present disclosure provides a substrate in the form of a peptide comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO: 3 or SEQ ID NO: 4 or SEQ ID NO: 5 or a variant thereof.

20 Still yet another embodiment of the present disclosure provides aminoglycoside such as ribostamycin, butirosin, paromomycin, neomycin, lividomycin, kanamycin, tobramycin, dibekacin, gentamicin, sismocin, netilimicin, isepamicin, arbekacin and amikacin.

In one embodiment the aminosugar is selected from a group consisting of 6-
25 amino-6-deoxyglucose, 6-amino-6-deoxymannose, 6-amino-6-deoxyallose, 6-amino-6-deoxyaltrose, 6-amino-6-deoxyidose, 6-amino-6-deoxygalactose and 6-amino-6-deoxytalose.

5 Yet another embodiment of the present disclosure provides a process of preparing the bioconjugate, wherein the polyamine is selected from a group consisting of spermine, spermidine and agmatine.

Still another embodiment of the present disclosure provides a process of preparing the bioconjugate, wherein the hydroxyamino acid is selected from a
10 group consisting of 4-amino-3-hydroxybutyric acid, 4-amino-2-hydroxybutyric acid and ethanolamine.

Another embodiment of the present disclosure provides a composition useful as therapeutic or diagnostic agent comprising the bioconjugate and pharmaceutically acceptable salts thereof.

15 Further embodiment of the present disclosure provides a kit useful for therapy or diagnosis comprising said bioconjugate and reagents suitable for administering said bioconjugate to an individual.

One embodiment of the present disclosure provides a method of detection of a ligand or a compound that binds to the bioconjugate disclosed in the present
20 invention.

One embodiment of the present disclosure provides a method for cloning, expression and purification of recombinant sortase. Detailed procedure is described in Example 1.

Another embodiment of the present disclosure provides a method for the
25 synthesis of peptides. For details refer Example 2.

Yet another embodiment of the present disclosure provides Sortase-catalyzed peptide ligation reaction. The ligation of various LPXTG containing peptides and sugar or aminoglycoside antibiotics is described (Example 3).

Still another embodiment of the present disclosure provides Sortase-catalyzed
30 ligation of model peptides to aminosugars. Sortase ligated LPXTG containing

5 substrates to aminosugar such as 6-amino-6-deoxyglucose but not to 2-amino-2-deoxyglucose glucosamine (Example 4).

Still yet another embodiment of the present disclosure provides a Sortase-catalyzed ligation of peptides to aminoglycoside antibiotics. The ability of sortase was tested to ligate peptides to aminoglycoside class of therapeutically important
10 antibiotics that are built up by a variety of aminosugars of the 6-amino or the 2, 6-diamino type besides containing several other amino functionalities. Details are provided in Example 5.

One embodiment of the present disclosure provides a process for preparation of bioconjugate by sortase catalyzed ligation reaction using YALPMTGK (SEQ ID
15 NO: 2) peptide and Kanamycin B antibiotic. For details refer Example 6.

Another embodiment of the present disclosure provides a process for preparation of bioconjugate by sortase catalyzed ligation reaction using YALPMTGK (SEQ ID NO: 2) peptide and Tobramycin antibiotic. For details refer Example 7.

Yet another embodiment of the present disclosure provides a process for
20 preparation of bioconjugate by sortase catalyzed ligation reaction using YALPMTGK (SEQ ID NO: 2) peptide and Paromomycin antibiotic. For details refer Example 8.

Still another embodiment of the present disclosure provides a process for preparation of bioconjugate by sortase catalyzed ligation reaction using
25 YALPMTGK (SEQ ID NO: 2) peptide and Ribostamycin antibiotic. For details refer Example 9.

Still yet another embodiment of the present disclosure provides a process for preparation of bioconjugate by sortase catalyzed ligation reaction using YALPMTGK (SEQ ID NO: 2) peptide and Neomycin antibiotic. For details refer
30 Example 10.

5 One embodiment of the present disclosure provides a process for preparation of bioconjugate by sortase catalyzed ligation reaction using (R)₉LPMTGK (SEQ ID NO: 4) peptide and Kanamycin B antibiotic. For details refer Example 11.

Another embodiment of the present disclosure provides a process for preparation of bioconjugate by sortase catalyzed ligation reaction using (R)₉LPMTGK (SEQ
10 ID NO: 4) peptide and Tobramycin antibiotic. For details refer Example 12.

Yet another embodiment of the present disclosure provides a process for preparation of bioconjugate by sortase catalyzed ligation reaction using (R)₉LPMTGK (SEQ ID NO:4) peptide and Paromomycin antibiotic. For details refer Example 13.

15 Still another embodiment of the present disclosure provides a process for preparation of bioconjugate by sortase catalyzed ligation reaction using (R)₉LPMTGK (SEQ ID NO: 4) peptide and Ribostamycin antibiotic. For details refer Example 14.

Still yet another embodiment of the present disclosure provides a process for
20 preparation of bioconjugate by sortase catalyzed ligation reaction using Tat and Rev mimetics to antibiotics. Ligation of peptides derived from Tat and Rev protein of HIV to aminoglycoside antibiotics was considered. Tat and Rev are two essential regulatory proteins that play important roles in HIV replication. For details refer Example 15.

25 One embodiment of the present disclosure provides a method of peptide ligation to amikacin and butirosin A. For details refer Example 16.

Another embodiment of the present disclosure provides a method of Sortase-catalyzed peptide ligation to polyamine spermine. For details refer Example 17.

While particular embodiments of the subject invention have been described, it
30 will be obvious to those skilled in the art that various changes and modifications of the subject invention can be made without departing from the spirit and scope

5 of the invention. In addition, while the present invention has been described in connection with certain specific embodiments thereof, it is to be understood that this is by way of illustration and not by way of limitation and the scope of the invention is defined by the appended claims which should be construed as broadly as the prior art will permit.

10 **EXAMPLES**

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and the description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments
15 below are all and only experiments performed.

Example 1

Cloning, expression and purification of recombinant sortase

The forward primer (SEQ ID NO: 6) and reverse primer (SEQ ID NO: 7) were used to amplify the SrtA_{Δ59} sequence corresponding to amino acids 60-204 from
20 the genomic DNA of *Staphylococcus aureus* Mu50 strain.

FP 5'-GATATACATATGCAAGCTAAACCTCAAATTCCG-3' SEQ ID NO:
6

RP 5'-GTGGTGCTCGAGTTTGACTTCTGTAGCTACAAAGAT-3' SEQ ID
NO: 7

25 The resulting amplicon was ligated into pGEM-T Easy vector, transformed into *Escherichia coli* (*E. coli*) XL-I Blue competent cells and selected from Luria-Bertani (LB) agar plates containing 50µg/ml ampicillin. The selected clones were verified by DNA sequencing for the presence of the desired construct. Plasmid DNA isolated from the positive clones was digested with *Nde*I and *Xho*I and
30 ligated into pET23b vector for expressing a recombinant sortase with a C-

5 terminal hexa-histidine tag. The ligation mixture was transformed into *E. coli*
XLI Blue competent cells and selected from 50µg/ml ampicillin containing LB
agar plates. Plasmid DNA isolated from the positive clones was used to transform
E. coli BL21 (DE3) competent cells. The transformed clones were propagated in
LB broth at 37°C for 3 hours or till the OD₆₀₀ reached 0.6 and the expression was
10 induced by addition of IPTG to a final concentration of 0.2mM, at 30°C for 3
hours. The induced cells were pelleted, resuspended in 10mM Tris-HCl, pH 7.5,
50mM NaCl, 1mM 2-mercaptoethanol (β-ME) and lysed by sonication. The
protein in the lysate supernatant was purified by Ni-NTA affinity
chromatography. The purified protein was freed of excess imidazole using a
15 10DG desalting column. The identity of recombinant sortase (SrtA_{Δ59}) was
established by Electrospray (ES) mass spectrometry (MS). The experimental
mass (17864.78 Da) was in agreement with the calculated value (17865 Da).
Other methods well known in the art can also be used.

Example 2

20 Synthesis of peptides

The peptides were synthesized by standard solid phase synthesis protocols using
Fmoc chemistry on a semi-automated peptide synthesizer. Wang resin preloaded
with the desired amino acid was used as the starting material. The coupling and
deprotection was monitored at every step by the Kaiser test for free amines.
25 Before each coupling step and on completion of the synthesis, the N-terminal
Fmoc group was removed using 20% piperidine (v/v in DMF). The peptides were
cleaved from the resin and the side chains deprotected with a mixture containing
trifluoro acetic acid (TFA), ethanediol, phenol, thioanisole and water (80:5:5:5:5,
v/v). The resin was removed by filtration and the crude peptides were precipitated
30 using cold diethyl ether. The peptides were purified to ≥98% by RPHPLC,
lyophilized and stored at -70°C. The chemical identity of the peptides was
checked by mass spectrometry. Other methods well known in the art may be used
for the synthesis of peptides or polypeptides or proteins.

5 **Example 3**

Sortase-catalyzed peptide ligation reaction

The ligation of various substrate comprising LPXTG peptide motif capable of recognizing sortase with biomolecule such as aminoglycoside, hexopyranose, polyamines, aminosugars, hydroxyamino acids, hydroxyamino acid esters, aminolipids and any other compound comprising these moieties was carried out in 0.3M Tris-acetate buffer (pH 7.5) containing 150mM NaCl, 5mM CaCl₂, and 2mM 2-mercaptoethanol. Each assay was set up in a 0.1 ml volume that contained 0.5 mM peptide, 1 mM sugar or antibiotics and 50 μM sortase. The reaction was allowed to proceed at 37°C for 4-6 hours, quenched by addition of 20 -fold excess of 0.1% trifluoroacetic acid (TFA) and analyzed by RPHPLC using acetonitrile-water-TFA solvent system. The reaction products were characterized by ESMS and/or MALDI-TOF mass spectrometry.

Example 4

Sortase-catalyzed ligation of model peptides or polypeptides to aminosugars

Sortase was ligated to two model substrates containing LPXTG motif, YALPETGK (SEQ ID NO: 1) and YALPMTGK (SEQ ID NO: 2) with aminosugar, namely, 6-amino-6-deoxyglucose. However, other peptides or polypeptides and sugar substrates well known in the art can similarly be used. The peptide YALPMTGK (SEQ ID NO: 2) and the sugar, 6-amino-6-deoxyglucopyranose (adg) were taken in 0.05M Tris-acetate buffer (pH 7.5) (containing 150mM NaCl, 5mM CaCl₂, and 2mM 2-mercaptoethanol) and incubated with sortase at about 37°C for about 4-6 hours. The reaction was quenched by addition of 20 to 40-fold excess of 0.1% trifluoroacetic acid (TFA). The reaction mixture was analyzed by RPHPLC using acetonitrile-water-TFA solvent system. Reaction products obtained from RPHPLC were characterized by ESMS. The observed mass of the reaction product was 856.62 Da and the expected theoretical mass of YALPMT-adg conjugate was 856.07 Da. The

5 RPHPLC of the reaction mixture followed by ESMS analyses of the product indeed confirmed the formation of the expected peptide-sugar conjugate (Refer table 2).

The chromatographic profile of the sample that contained 6-amino-6-deoxyglucose and YALPETGK (SEQ ID NO: 1) revealed two new peaks [Figure
10 1A (a), 0 h control; (b), 6 h reaction with glucosamine; (c), 6 h reaction with 6-deoxy-6-aminoglucopyranose, Figure 1 B) ESI-MS of the product (indicated by an arrow in c) isolated from RPHPLC.] Electrospray mass spectrometric analyses (Table 2) of the new peaks were in accordance with the calculated mass of YALPET (hydrolysed product) or a sugar-TEPLAY adduct suggesting that the
15 above amino sugar indeed acted as a nucleophile in the transamidation reaction catalyzed by sortase. The ligation reaction with the above peptides proceeded in much the same way when 6-amino-6-deoxymannose was used as an aminosugar.

Similarly a substrate containing (2-amino-2-deoxyglucose) glucosamine was ligated with either YALPETGK (SEQ ID NO: 1) or YALPMTGK (SEQ ID NO:
20 2). RPHPLC profile of this reaction revealed that the substrate peptide was hydrolyzed to YALPET without the formation of an adduct.

Example 5

Sortase-catalyzed ligation of peptides or polypeptides to aminoglycoside antibiotics

25 The ability of sortase was tested to ligate peptides or polypeptides to aminoglycoside class of therapeutically important antibiotics that are built up by a variety of aminosugars of the 6-amino or the 2, 6-diamino type besides containing several other amino functionalities. The central scaffold of aminoglycoside antibiotics is the 2-deoxystreptamine ring to which aminosugars
30 are substituted at positions 4 and 6 (as in tobramycin and kanamycin) or 4 and 5 (as in ribostamycin, neomycin and paramomycin). The sortase-mediated conjugation of the aminoglycoside antibiotics with YALPETGK (SEQ ID NO: 1)

5 or YALPMTGK (SEQ ID NO: 2) model peptide substrates was tested. Other sequences like SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5 or any polypeptide containing LPXTG sequence motif can be similarly used.

Example 6

Synthesis of sortase catalyzed ligation product formed from YALPMTGK (SEQ ID NO: 2) peptide and Kanamycin B antibiotic

The peptide YALPMTGK (SEQ ID NO:2) and the antibiotic, Kanamycin B, were taken in 0.05M Tris-acetate buffer (pH 7.5) (containing 150mM NaCl, 5mM CaCl₂, and 2mM 2-mercaptoethanol) and incubated with sortase at 37°C for 4-6 hours. The reaction was quenched by addition of 20 to 40-fold excess of 0.1% trifluoroacetic acid (TFA). The reaction mixture was analyzed by RPHPLC using acetonitrile-water-TFA solvent system. Reaction products obtained from RPHPLC were characterized by ESMS. The observed mass of the reaction product was 1159.93 Da and the expected theoretical mass of YALPMT-Kanamycin B conjugate was 1160.9 Da. The RPHPLC of the reaction mixture followed by ESMS analyses of the product indeed confirmed the formation of the expected peptide-antibiotic conjugate. (Refer table 2).

Example 7

Synthesis of sortase catalyzed ligation product formed from YALPMTGK (SEQ ID NO: 2) peptide and Tobramycin antibiotic

25 The peptide YALPMTGK (SEQ ID NO:2) and the antibiotic, Tobramycin, were taken in 0.05M Tris-acetate buffer (pH 7.5) (containing 150mM NaCl, 5mM CaCl₂, and 2mM 2-mercaptoethanol) and incubated with sortase at 37°C for 4-6 hours. The reaction was quenched by addition of 20 to 40-fold excess of 0.1% trifluoroacetic acid (TFA). The reaction mixture was analyzed by RPHPLC using acetonitrile-water-TFA solvent system. Reaction products obtained from RPHPLC were characterized by ESMS. The observed mass of the reaction

5 product was 1144.03 Da and the expected theoretical mass of YALPMT-Tobramycin conjugate was 1144.5 Da. The RPHPLC of the reaction mixture followed by ESMS analyses of the product indeed confirmed the formation of the expected peptide-antibiotic conjugate. (Refer table 2).

Example 8

10 Synthesis of sortase catalyzed ligation product formed from YALPMTGK (SEQ ID NO: 2) peptide and Paromomycin antibiotic

The peptide YALPMTGK (SEQ ID NO:2) and the antibiotic, Paromomycin, were taken in 0.05M Tris-acetate buffer (pH 7.5) (containing 150mM NaCl, 5mM CaCl₂, and 2mM 2-mercaptoethanol) and incubated with sortase at 37°C for
15 4-6 hours. The reaction was quenched by addition of 20 to 40-fold excess of 0.1% trifluoroacetic acid (TFA). The reaction mixture was analyzed by RPHPLC using acetonitrile-water-TFA solvent system. Reaction products obtained from RPHPLC were characterized by ESMS. The observed mass of the reaction product was 1292.09 Da and the expected theoretical mass of YALPMT-
20 Paromomycin conjugate was 1292.6 Da. The RPHPLC of the reaction mixture followed by ESMS analyses of the product indeed confirmed the formation of the expected peptide-antibiotic conjugate. (Refer table 2).

Example 9

25 Synthesis of sortase catalyzed ligation product formed from YALPMTGK (SEQ ID NO: 2) peptide and Ribostamycin antibiotic

The peptide YALPMTGK (SEQ ID NO:2) and the antibiotic, Ribostamycin, were taken in 0.05M Tris-acetate buffer (pH 7.5) (containing 150mM NaCl, 5mM CaCl₂, and 2mM 2-mercaptoethanol) and incubated with sortase at 37°C for
4-6 hours. The reaction was quenched by addition of 20 to 40-fold excess of
30 0.1% trifluoroacetic acid (TFA). The reaction mixture was analyzed by RPHPLC using acetonitrile-water-TFA solvent system. Reaction products obtained from

5 RPHPLC were characterized by ESMS. The observed mass of the reaction product was 1130.86 Da and the expected theoretical mass of YALPMT-Ribostamycin conjugate was 1131.5 Da. The RPHPLC of the reaction mixture followed by ESMS analyses of the product indeed confirmed the formation of the expected peptide-antibiotic conjugate. (Refer table 2).

10 **Example 10**

Synthesis of sortase catalyzed ligation product formed from YALPMTGK (SEQ ID NO: 2) peptide and Neomycin antibiotic

The peptide YALPMTGK (SEQ ID NO:2) and the antibiotic, Neomycin, were taken in 0.05M Tris-acetate buffer (pH 7.5) (containing 150mM NaCl, 5mM
15 CaCl₂, and 2mM 2-mercaptoethanol) and incubated with sortase at 37°C for 4-6 hours. The reaction was quenched by addition of 20 to 40-fold excess of 0.1% trifluoroacetic acid (TFA). The reaction mixture was analyzed by RPHPLC using acetonitrile-water-TFA solvent system. Reaction products obtained from RPHPLC were characterized by ESMS. The observed mass of the reaction
20 product was 1193.47 Da and the expected theoretical mass of YALPMT-Neomycin conjugate was 1194.3 Da. The RPHPLC of the reaction mixture followed by ESMS analyses of the product indeed confirmed the formation of the expected peptide-antibiotic conjugate. (Refer table 2).

Example 11

25 Synthesis of sortase catalyzed ligation product formed from (R)₉LPMTGK (SEQ ID NO: 4) peptide and Kanamycin B antibiotic

The peptide (R)₉LPMTGK (SEQ ID NO: 4) and the antibiotic, Kanamycin B, were taken in 0.05M Tris-acetate buffer (pH 7.5) (containing 150mM NaCl, 5mM CaCl₂, and 2mM 2-mercaptoethanol) and incubated with sortase at 37°C for
30 4-6 hours. The reaction was quenched by addition of 20 to 40-fold excess of 0.1% trifluoroacetic acid (TFA). The reaction mixture was analyzed by RPHPLC

5 using acetonitrile-water-TFA solvent system. Reaction products obtained from
RPHPLC were characterized by ESMS. The observed mass of the reaction
product was 2331.8 Da and the expected theoretical mass of (R)₉LPMT -
Kanamycin B conjugate was 2331.63 Da. The RPHPLC of the reaction mixture
followed by ESMS analyses of the product indeed confirmed the formation of the
10 expected peptide-antibiotic conjugate. (Refer table 2).

Example 12

Synthesis of sortase catalyzed ligation product formed from (R)₉LPMTGK (SEQ ID NO:4) peptide and Tobramycin antibiotic

The peptide (R)₉LPMTGK (SEQ ID NO:4) and the antibiotic, Tobramycin, were
15 taken in 0.05M Tris-acetate buffer (pH 7.5) (containing 150mM NaCl, 5mM
CaCl₂, and 2mM 2-mercaptoethanol) and incubated with sortase at about 37°C for
about 4-6 hours. The reaction was quenched by addition of 20 to 40-fold excess
of 0.1% trifluoroacetic acid (TFA). The reaction mixture was analyzed by
RPHPLC using acetonitrile-water-TFA solvent system. Reaction products
20 obtained from RPHPLC were characterized by ESMS. The observed mass of the
reaction product was 2315.9 Da and the expected theoretical mass of (R)₉LPMT -
Tobramycin conjugate was 2315.5 Da. The RPHPLC of the reaction mixture
followed by ESMS analyses of the product indeed confirmed the formation of the
expected peptide-antibiotic conjugate (Refer table 2).

25 Example 13

Synthesis of sortase catalyzed ligation product formed from (R)₉LPMTGK (SEQ ID NO:4) peptide and Paromomycin antibiotic

The peptide (R)₉LPMTGK (SEQ ID NO: 4) and the antibiotic, Paromomycin,
were taken in 0.05M Tris-acetate buffer (pH 7.5) (containing 150mM NaCl,
30 5mM CaCl₂, and 2mM 2-mercaptoethanol) and incubated with sortase at about
37°C for about 4-6 hours. The reaction was quenched by addition of 20 to 40-fold

5 excess of 0.1% trifluoroacetic acid (TFA). The reaction mixture was analyzed by
RPHPLC using acetonitrile-water-TFA solvent system. Reaction products
obtained from RPHPLC were characterized by ESMS. The observed mass of the
reaction product was 2463.17 Da and the expected theoretical mass of (R)₉LPMT
- Paromomycin conjugate was 2463.63 Da. The RPHPLC of the reaction mixture
10 followed by ESMS analyses of the product indeed confirmed the formation of the
expected peptide-antibiotic conjugate (Refer table 2).

Example 14

Synthesis of sortase catalyzed ligation product formed from (R)₉LPMTGK (SEQ ID NO: 4) peptide and Ribostamycin antibiotic

15 The peptide (R)₉LPMTGK (SEQ ID NO: 4) and the antibiotic, Ribostamycin,
were taken in 0.05M Tris-acetate buffer (pH 7.5) (containing 150mM NaCl,
5mM CaCl₂, and 2mM 2-mercaptoethanol) and incubated with sortase at about
37°C for about 4-6 hours. The reaction was quenched by addition of 20 to 40-fold
excess of 0.1% trifluoroacetic acid (TFA). The reaction mixture was analyzed by
20 RPHPLC using acetonitrile-water-TFA solvent system. Reaction products
obtained from RPHPLC were characterized by ESMS. The observed mass of the
reaction product was 2302.9 Da and the expected theoretical mass of (R)₉LPMT -
Ribostamycin conjugate was 2303.53 Da. The RPHPLC of the reaction mixture
followed by ESMS analyses of the product indeed confirmed the formation of the
25 expected peptide-antibiotic conjugate. (Refer table 2).

Example 15

Sortase-catalyzed ligation of Tat and Rev mimetics to antibiotics

Ligation of peptides derived from Tat and Rev protein of HIV to aminoglycoside
antibiotics was considered. Tat and Rev are two essential regulatory proteins that
30 play important roles in HIV replication. Both Tat and Rev act through structured
viral RNA target sites, TAR in the case of Tat and RRE in the case of Rev (14).

5 Short arginine rich peptide sequences derived from Tat and Rev can mimic the
action of respective parent proteins (15). Besides, a nona-arginine peptide (R₉) is
known to bind to TAR with the same affinity and specificity as the wild type Tat
peptide. Since aminoglycoside antibiotics (such as neomycin, tobramycin,
ribostamycin etc) also bind to TAR and RRE RNA (16), bio-conjugates
10 consisting of aminoglycoside antibiotics and Tat and/or Rev peptide mimics
(natural or designed) are likely to exert synergistic action and be potent inhibitors
of HIV replication.

The sortase-catalyzed ligation reaction of a non-arginine sequence carrying a
sortase recognizable LPXTGK (X= E or M) motif (RRRRRRRRRLPXTGK)
15 with the antibiotics proceeded in much the same way as the model peptide
substrate [(Figure 9 (b))]. Likewise, a peptide sequence spanning residues 34-50
of Rev and appended with the sortase recognition sequence
(TRQARRNRRRRWRERQRGGGLPETGK, SEQ ID NO: 5) also formed
specific conjugates with neomycin B and tobramycin [Figure 9(c)] The
20 experimental mass of the conjugates was in accord with the calculated mass
(Table 2).

Example 16

Peptide ligation to amikacin and butirosin A

The sortase-catalyzed ligation of peptides to amikacin and butirosin A was
25 investigated. These antibiotics, of the kanamycin and ribostamycin class
respectively, are unique in that they carry a 4-amino-2-hydroxybutyrate (*ahba*)
side chain on the C-1 amino group of the central deoxystreptamine ring. Unlike
the peptide ligation reactions with antibiotics described above, the HPLC
chromatographic profile of sortase peptide substrates (YALPXTGK, X = E or M)
30 reacted with amikacin or butirosin A showed two product peaks [Figures 7, A
and B] Interestingly, both the product peaks of each antibiotics yielded identical
mass (1260.67 Da in the case of amikacin and 1230.67 Da in the case of butirosin
A) corresponding to a 1:1 ligation of the peptide to antibiotics when analyzed by

- 5 MALDI. The results suggest that each product represented a distinct site of peptide ligation. Given that the difference between their respective parent antibiotics (kanamycin and ribostamycin) was the presence of *ahba* group, the two products may represent conjugation of peptide either to the 6-amine in the A-ring or the amine of the *ahba* side chain of the 6-deoxystreptamine ring.
- 10 Consistent with this, sortase was able to transfer relevant peptide substrate to 4-amino-2-hydroxybutyric acid as well as to 4-amino-3-hydroxybutyric acid (Figure 8).

Example 17

Sortase-catalyzed peptide ligation to polyamine spermine

- 15 We also explored the ability of sortase to conjugate peptide substrate to polyamines. The HPLC profile of a reaction mixture incubated with YALPETGK (SEQ ID NO: 1) peptide and spermine revealed the formation a product which was characterized by ESMS as a spermine-peptide adduct (Figure 10, Table 2).

- 20 Table: 1 ESI mass analyses of synthetic peptides used in sortase-mediated ligation reactions

SEQ ID NO	Sequence	Observed	Calculated
1	YALPETGK	877.55	877.99
2	YALPMTGK	879.53	880.07
3	RRRRRRRRRLPETGK	2049.0	2049.42
4	RRRRRRRRRLPMTGK	2051.2	2051.50
5	TRQARRNRRRRWRERQGGGLPETGK	3234.2	3234.64

5 Table: 2 ESI mass of sortase-catalyzed ligation product formed from LPXTG containing peptides and various amino nucleophiles

S. No.	Peptide	Nucleophile	Product	Observed mass (Da)	Expected mass (Da)
1	YALPMTGK	adg	adg-TMPLAY	855.62	855.85
2	YALPMTGK	Kanamycin A	Kanamycin A-TMPLAY	1160.34	1161.64
3	YALPMTGK	Kanamycin B	Kanamycin B- TMPLAY	1159.93	1160.64
4	YALPMTGK	Tobramycin	Tobramycin- TMPLAY	1144.03	1144.35
5	YALPMTGK	Paromomycin	Paromomycin- TMPLAY	1292.09	1292.47
6	YALPMTGK	Ribostamycin	Ribostamycin- TMPLAY	1130.86	1131.31
7	YALPMTGK	Neomycin B	Neomycin B- TMPLAY	1290.74	1291.48
8	R ₉ LPMTGK	Tobramycin	Tobramycin- TMPLR ₉	2315.90	2315.79
9	R ₉ LPMTGK	Paromomycin	Paromomycin- TMPLR ₉	2463.17	2463.91
10	R ₉ LPMTGK	Ribostamycin	Ribostamycin- TMPLR ₉	2302.92	2303.75
11	R ₉ LPETGK	Neomycin B	Neomycin B- TEPLR ₉	2460.03	2460.84
12	YALPETGK	adg	adg- TEPLAY	853.37	853.76
13	YALPETGK	Kanamycin A	Kanamycin A- TEPLAY	1158.49	1159.26
14	YALPETGK	Tobramycin	Tobramycin- TEPLAY	1142.27	1141.57
15	YALPETGK	Ribostamycin	Ribostamycin- TEPLAY	1128.56	1129.23
16	YALPETGK	Paromomycin	Paromomycin- TEPLAY	1289.63	1290.39
17	YALPETGK	Neomycin B	Neomycin B- TEPLAY	1288.63	1289.4
18	Rev-LPETGK	Tobramycin	Tobramycin- TEPL-Rev	3498.30	3498.93
19	Rev-LPETGK	Neomycin B	Neomycin B- TEPL-Rev	3646.55	3646.06
20	YALPETGK	ahba	ahba- TEPLAY	793.21	793.88
21	YALPETGK	Spermine	Spermine- TEPLAY	876.89	877.10
22	YALPETGK	adm	adm-TEPLAY	853.94	853.57

Abbreviations used in the table: adg, 6-amino-6-deoxyglucose; adm, 6-amino-6-deoxymannose; Rev, TRQARRNRRRWRERQRGGG; ahba, 4-amino-3-

10 hydroxybutyric acid; Spermine, N, N'-Bis(3-aminopropyl)-1,4-butanediamine

5 **What is claimed is:**

1. A novel therapeutic and diagnostic bioconjugate useful for target delivery of a compound, wherein said bioconjugate comprising:
 - a. a substrate comprising LPXTG peptide motif capable of recognizing sortase, wherein said substrate is selected from a group consisting of peptides, polypeptides, proteins, glycoprotein, lipoprotein, antibodies, radionucleotides, fluorophores, ligand chromophore and any compound comprising the LPXTG peptide motif; and
 - b. a biomolecule selected from a group consisting of aminoglycoside, aminosugar, polyamine, hydroxyamino acid, hydroxyamino acid ester, aminolipid and any other compound comprising these moieties.
2. The bioconjugate as claimed in claim 1, wherein the substrate is covalently linked to the biomolecule by a sortase catalyzed ligation mechanism.
3. The bioconjugate as claimed in claim 1, wherein the substrate is a peptide having amino acid sequence selected from a group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and a variant thereof.
4. The bioconjugate as claimed in claim 1, wherein the aminoglycoside is selected from a group consisting of ribostamycin, butirosin, paromomycin, neomycin, lividomycin, kanamycin, tobramycin, dibekacin, gentamicin, sisomicin, netilmicin, isepamicin, arbekacin, amikacin, streptomycin, apramycin, hygromycin, neamine, vancomycin and kasugamycin.
5. The bioconjugate as claimed in claim 1, wherein the aminosugar is selected from a group consisting of 6-amino-6-deoxyglucose, 6-amino-6-deoxymannose, 6-amino-6-deoxyallose, 6-amino-6-deoxyaltrose, 6-

- 5 amino-6-deoxyidose, 6-amino-6-deoxygalactose and 6-amino-6-deoxytalose.
6. The bioconjugate as claimed in claim 1, wherein the polyamine is selected from a group consisting of spermine, spermidine and agmatine
7. The bioconjugate as claimed in claim 1, wherein the hydroxyamino acid
10 is selected from a group consisting of 4-amino-3-hydroxybutyric acid, 4-amino-2-hydroxybutyric acid and etahnolamine.
8. The bioconjugate as claimed in claim 1, wherein the hydroxyamino acid ester is selected from a group consisting of 4-amino-3-hydroxybutyryl stearate, 4-amino-3-hydroxybutyryl palmitate, 4-amino-3-
15 hydroxybutyryl acetate, 4-amino-3-hydroxybutyryl propionate, butyrate/ or 4-amino-2-hydroxybutyryl-acetate, 4-amino-2-hydroxybutyryl-propionate, 4-amino-2-hydroxybutyryl-butyrate, 4-amino-2-hydroxybutyryl-stearate, 4-amino-2-hydroxybutyrylpalmitate, 4-amino-2-hydroxy-butyryl-coenzyme A, 4-amino-3-hydroxybutyrylpalmitate, 4-
20 amino-2-hydroxybutyryl-coenzyme A.
9. The bioconjugate as claimed in claim 1, wherein the aminolipid is either N-[(3-hexadecanoyloxy)hexadecanoyl] ornithine or virodhamine.
10. A process of preparing the bioconjugate as claimed in claim 1, said process comprising:
- 25 a. providing a substrate comprising LPXTG peptide motif capable of recognizing sortase, wherein said substrate is selected from a group consisting of peptides, polypeptides, proteins, glycoprotein, lipoprotein, antibodies, radionucleotides, fluorphores, ligand chromophore and any compound comprising the LPXTG peptide motif;
- 30 b. providing a biomolecule selected from a group consisting of aminoglycoside, aminosugar, polyamine, hydroxyamino acid,

- 5 hydroxyamino acid ester, aminolipid and any compound comprising these moieties;
- c. providing sortase to catalyze the ligation reaction of said substrate and said biomolecule under suitable conditions to obtain said bioconjugate
- 10 11. The process of preparing the bioconjugate as claimed in claim 10, wherein the sortase is isolated from *Staphylococcus aureus*.
12. The process of preparing the bioconjugate as claimed in claim 10, wherein the substrate is a peptide comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO: 3 or SEQ ID NO: 4 or SEQ ID NO: 5 or a variant thereof.
- 15 13. The process of preparing the bioconjugate as claimed in claim 10, wherein the aminoglycoside is selected from a group consisting of ribostamycin, butirosin, paromomycin, neomycin, lividomycin, kanamycin, tobramycin, dibekacin, gentamicin, sismocin, netilmicin, isepamicin, arbekacin and amikacin.
- 20 14. The process of preparing the bioconjugate as claimed in claim 10, wherein the aminosuagar is selected from a group consisting of 6- amino-6-deoxyglucose, 6-amino-6-deoxymannose, 6-amino-6 deoxyallose, 6-amino-6-deoxyaltrose, 6-amino-6-deoxyidose, 6-amino-6-deoxygalactose and 6-amino-6-deoxytalose.
- 25 15. The process of preparing the bioconjugate as claimed in claim 10, wherein the polyamine is selected from a group consisting of spermine, spermidine and agmatine.
16. The process of preparing the bioconjugate as claimed in claim 10, wherein the hydroxyamino acid is selected from a group consisting of 4-amino-3-hydroxybutyric acid, 4-amino-2-hydroxybutyric acid and etahnolamine.
- 30

- 5 17. A composition useful as therapeutic or diagnostic agent comprising the
 bioconjugate as claimed in claim 1 and pharmaceutically acceptable
 carrier.
18. A kit useful for therapy or diagnosis comprising said bioconjugate as
 claimed in claim 1 and reagents suitable for administering said
10 bioconjugate to an individual.

SEQUENCE LISTING.ST25
SEQUENCE LISTING

<110> National Institute of Immunology
Roy, Rajendra Prasad
Samantaray, Sharmishtha

<120> BIOCONJUGATES USEFUL FOR THERAPY AND DIAGNOSIS AND PROCESS
THEREOF

<130> PCT0055

<150> 797/DEL/2006

<151> 2006-03-22

<160> 7

<170> PatentIn version 3.3

<210> 1

<211> 8

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC SEQUENCE

<400> 1

Tyr Ala Leu Pro Glu Thr Gly Lys
1 5

<210> 2

<211> 8

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC SEQUENCE

<400> 2

Tyr Ala Leu Pro Met Thr Gly Lys
1 5

<210> 3

<211> 15

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC SEQUENCE

<400> 3

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Leu Pro Glu Thr Gly Lys
1 5 10 15

<210> 4

<211> 15

<212> PRT

SEQUENCE LISTING.ST25

<213> ARTIFICIAL

<220>

<223> SYNTHETIC SEQUENCE

<400> 4

Arg Arg Arg Arg Arg Arg Arg Arg Arg Leu Pro Met Thr Gly Lys
1 5 10 15

<210> 5

<211> 26

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC SEQUENCE

<400> 5

Thr Arg Gln Ala Arg Arg Asn Arg Arg Arg Arg Trp Arg Glu Arg Gln
1 5 10 15

Arg Gly Gly Gly Leu Pro Glu Thr Gly Lys
20 25

<210> 6

<211> 33

<212> DNA

<213> ARTIFICIAL

<220>

<223> SYNTHETIC SEQUENCE

<400> 6

gatatacata tgcaagctaa acctcaaatt ccg

33

<210> 7

<211> 36

<212> DNA

<213> ARTIFICIAL

<220>

<223> SYNTHETIC SEQUENCE

<400> 7

gtgggtgctcg agtttgactt ctgtagctac aaagat

36